Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Acumen Pharmaceuticals Inc (NASDAQ: ABOS) closed at $3.29 down -5.46% from its previous closing price of $3.48. In other words, the price has decreased by -$5.46 from its previous closing price. On the day, 0.54 million shares were traded. ABOS stock price reached its highest trading level at $3.6 during the session, while it also had its lowest trading level at $3.21.
Ratios:
For a deeper understanding of Acumen Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 30.20 and its Current Ratio is at 30.20. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.12.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on July 26, 2024, initiated with a Buy rating and assigned the stock a target price of $7.
On December 12, 2023, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $8.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 19 ’24 when OConnell Daniel Joseph sold 15,200 shares for $3.47 per share. The transaction valued at 52,753 led to the insider holds 502,485 shares of the business.
Meisner Derek M sold 8,933 shares of ABOS for $31,048 on Jan 19 ’24. The Chief Legal Officer & Corp Sec now owns 108,867 shares after completing the transaction at $3.48 per share. On Jan 18 ’24, another insider, Zuga Matt, who serves as the CFO & Chief Business Officer of the company, sold 4,242 shares for $3.71 each. As a result, the insider received 15,717 and left with 211,445 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABOS now has a Market Capitalization of 197662544 and an Enterprise Value of -24267530.
Stock Price History:
Over the past 52 weeks, ABOS has reached a high of $7.62, while it has fallen to a 52-week low of $1.81. The 50-Day Moving Average of the stock is 15.86%, while the 200-Day Moving Average is calculated to be 1.97%.
Shares Statistics:
For the past three months, ABOS has traded an average of 424.30K shares per day and 439970 over the past ten days. A total of 57.91M shares are outstanding, with a floating share count of 44.37M. Insiders hold about 26.14% of the company’s shares, while institutions hold 63.99% stake in the company. Shares short for ABOS as of 1721001600 were 1656370 with a Short Ratio of 3.90, compared to 1718323200 on 710546. Therefore, it implies a Short% of Shares Outstanding of 1656370 and a Short% of Float of 3.6999999999999997.
